AVDL•benzinga•
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ
Summary
Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2025 by benzinga